Chemotherapy for advanced germ cell tumors

Journal of Clinical Oncology

Volumn 24, Issue 35, 2006, Pages 5493-5502

  Kondagunta, G Varuni ^a   Motzer, Robert J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT; BEP PROTOCOL;

ALGORITHM; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; SEMINOMA; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY;

EID: 34247354937     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.7882     Document Type: Review

References (80)

1. IGCCCG: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers - International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
2. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
3. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
4. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
5. de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837-1843, 1997
6. Loehrer PJ Sr, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
7. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
8. Horwich A, Sleijfer DT, Fossa SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844-1852, 1997
9. Culine S, Kerbrat P, Bouzy J, et al: The optimal chemotherapy regimen for good-risk metastatic non-seminomatous germ cell tumors (MNSGCT) is 3 cycles of bleomycin, etoposide, and cisplatin: Mature results of a randomized trial. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL
10. Toner GC, Stockier MR, Boyer MJ, et al: Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: A randomised trial - Australian and New Zealand Germ Cell Trial Group. Lancet 357:739-745, 2001
11. Kosty MP: Genitourinary (nonprostate) cancer. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL
12. Baniel J, Foster RS, Rowland RG, et al: Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153:976-980, 1995
13. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000
14. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003
15. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
16. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006
17. Kondagunta GV, Bacik J, Bajorin D, et al: Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23:9290-9294, 2005
18. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311-1314, 1995
19. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
20. Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287-1293, 1998
21. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with BOPA/IP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692-701, 1998
22. Bajorin DF NC, Margolin KA, et al.: Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA
23. Husband DJ, Green JA: POMB/ACE chemotherapy in non-seminomatous germ cell tumours: Outcome and importance of dose intensity. Eur J Cancer 28:86-91, 1992
24. Blanke C, Loehrer PJ, Nichols CR, et al: A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors. Am J Clin Oncol 19:487-491, 1996
25. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97:1869-1875, 2003
26. de Wit R, Louwerens M, de Mulder PH, et al: Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP. Int J Cancer 83:831-833, 1999
27. Motzer RJ, Gulati SC, Crown JP, et al: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 69:550-556, 1992
28. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
29. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
30. Decatris MP, Wilkinson PM, Welch RS, et al: High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity. Ann Oncol 11:427-434, 2000
31. Motzer RJ, Mazumdar M, Bajorin DF, et al: High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546-2552, 1997
32. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol (in press)
33. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
34. Murphy BA, Motzer RJ, Bosl GJ: Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors: the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs 10:327-330, 1992
35. Mazumdar M, Bajorin DF, Bacik J, et al: Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19:2534-2541, 2001
36. Toner GC, Geller NL, Tan C, et al: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50:5904-5910, 1990
37. Schmoll HJ, Kollmannsberger C, Metzner B, et al: Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083-4091, 2003
38. Motzer RJ, Geller NL, Tan CC, et al: Salvage chemotherapy for patients with germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310, 1991
39. Motzer RJ, Sheinfeld J, Mazumdar M, et al: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413-2418, 2000
40. Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
41. Saxman SB, Nichols CR, Einhorn LH: Salvage chemotherapy in patients with extragonadal non-seminomatous germ cell tumors: The Indiana University experience. J Clin Oncol 12:1390-1393, 1994
42. Linkesch W, Greinix HT, Hocker P, et al: Longterm follow up of phase I/II trial of ultra-high carboplatin, VP-16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 717)
43. Beyer J, Kramar A, Mandanas R, et al: High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-2645, 1996
44. Vaena DA, Abonour R, Einhorn LH: Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 21:4100-4104, 2003
45. Wheeler BM, Loehrer PJ, Williams SD, et al: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34, 1986
46. Harstrick A, Schmoll HJ, Wilke H, et al: Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9:1549-1555, 1991
47. Loehrer PJ Sr., Lauer R, Roth BJ, et al: Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540-546, 1988
48. Loehrer PJ Sr, Gonin R, Nichols CR, et al: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998
49. McCaffrey JA, Mazumdar M, Bajorin DF, et al: Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 15:2559-2563, 1997
50. Ghosn M, Droz JP, Theodore C, et al: Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin: A VIhP regimen. Cancer 62:24-27, 1988
51. Pizzocaro G, Salvioni R, Piva L, et al: Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors: Long-term results. Ann Oncol 3:211-216, 1992
52. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
53. Kondagunta GV, Bacik J, Donadio A, et al: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549-6555, 2005
54. Mardiak J, Salek T, Sycova-Mila Z, et al: Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: A phase II study. Neoplasma 52:497-501, 2005
55. Mead GM, Cullen MH, Huddart R, et al: A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: A Medical Research Council trial. Br J Cancer 93:178-184, 2005
56. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study - The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12:1223-1231, 1994
57. Bhatia S, Abonour R, Porcu P, et al: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351, 2000
58. Pico JL, Rosti G, Kramar A: Ea: A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16:1152-1159, 2005
59. Rick O, Bokemeyer C, Beyer J, et al: Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19:81-88, 2001
60. Rodenhuis S, de Wit R, de Mulder PH, et al: A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10:1467-1473, 1999
61. Kondagunta GV BJ, Bajorin DF, et al.: Sequential dose-intensive paclitaxel plus ifosfamide and carboplatin plus etoposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts). Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL
62. Lotz JP, Bui B, Gomez F, et al: Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation: Results of the phase II multicentric TAXIF trial. Ann Oncol 16:411-418, 2005
63. Motzer RJ, Mazumdar M, Sheinfeld J, et al: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18:1173-1180, 2000
64. Debono DJ, Heilman DK, Einhorn LH, et al: Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455-1464, 1997
65. Stephenson AJ, Sheinfeld J: The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol 22:225-235, 2004
66. Fox EP, Weathers TD, Williams SD, et al: Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11:1294-1299, 1993
67. Rick O BC, Christian J, et al: Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell tumors. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL
68. Vuky J, Bains M, Bacik J, et al: Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 19:682-688, 2001
69. Puc HS, Heelan R, Mazumdar M, et al: Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14:454-460, 1996
70. De Santis M, Becherer A, Bokemeyer C, et al: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol 22:1034-1039, 2004
71. Miller JC, Einhorn LH: Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 17:36-39, 1990
72. Bokemeyer C, Gerl A, Schoffski P, et al: Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512-516, 1999
73. Kollmannsberger C, Rick O, Derigs HG, et al: Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031-2037, 2002
74. Lewis DA BM, and Einhorn LH: Can patients (pts) with refractory germ cell tumors (GCT) be cured after progression following high dose chemotherapy (HDCT) with tandem transplant? Results with paclitaxel + gemcitabine, Presented at the 42nd Annual Meeting, of the American Society of Clinical Oncology June 2-6, 2006, Atlanta, GA
75. Faivre S, Raymond E, Woynarowski JM, et al: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117-123, 1999
76. Kollmannsberger C, Beyer J, Liersch R, et al: Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 22:108-114, 2004
77. Rothenberg ML, Sharma A, Weiss GR, et al: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 9:733-738, 1998
78. Hinton S, Catalano P, Einhorn LH, et al: Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20:1859-1863, 2002
79. Toner GC, Geller NL, Lin SY, et al: Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer 67:2049-2057, 1991
80. Broun ER, Nichols CR, Einhorn LH, et al: Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 68:1513-1515, 1991